ResultsIQ

ResultsIQ › Latest results › Aarti Drugs Limited

Aarti Drugs Limited Q1 FY27 results deck summary

NSE: AARTIDRUGS · BSE: 524348

Results deck of 1 Aug 2026, summarised by AI from the filing.

Q1 FY27 total revenue ₹703.6 cr (+19% YoY) and EBITDA ₹96.9 cr (+30% YoY), with Sayakha at ~65% utilization.

Key takeaways

  1. Q1 FY27 revenue Total revenue ₹703.6 cr (Q1 FY26: ₹590.8 cr, +19%); EBITDA ₹96.9 cr (Q1 FY26: ₹74.4 cr, +30%).
  2. Sayakha ramp-up Sayakha operated at nearly 65% utilization in Q1 FY27, contributing to backward integration.
  3. Regulated markets USFDA and UK approvals for facilities remain important growth drivers, supporting expansion in regulated markets.

Original filing on BSE

Aarti Drugs Limited Q1 FY27 results

As filed: Revenue ₹703 cr (+19% year on year), EBITDA ₹98.2 cr (+31% year on year), PAT ₹50.1 cr (−7% year on year), EBITDA margin 14.0% (+128 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹720 cr (+6% year on year), EBITDA ₹95.8 cr (+3% year on year), PAT ₹55.3 cr (−12% year on year), EBITDA margin 13.3% (−44 bps). Score 51 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin fell 44 bps year on year. Share price after the results: +1.1% in 28 days (Nifty 500: +0.3%).
  • Q3 FY26: Revenue ₹602 cr (+8% year on year), EBITDA ₹55.0 cr (−11% year on year), PAT ₹40.6 cr (+10% year on year), EBITDA margin 9.2% (−199 bps). Score 42 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was below it; profit growth was in line with it. EBITDA margin fell 199 bps year on year. Tax rate -40%. Revenue fell 8% from last quarter. Share price after the results: −7.6% in 30 days (Nifty 500: −3.2%).
  • Q2 FY26: Revenue ₹653 cr (+9% year on year), EBITDA ₹84.0 cr (+24% year on year), PAT ₹45.0 cr (+29% year on year), EBITDA margin 12.9% (+149 bps). Score 75 of 100, Above trend. Revenue and profit growth were above the company's own trend; EBITDA growth was well above it. EBITDA margin rose 149 bps year on year. Profit fell 17% from last quarter. Share price after the results: −17.2% in 28 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹591 cr (+6% year on year), EBITDA ₹75.0 cr (+15% year on year), PAT ₹54.0 cr (+64% year on year), EBITDA margin 12.7% (+98 bps). Score 74 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 98 bps year on year. Tax rate -6%. Revenue fell 13% from last quarter. Share price after the results: −7.0% in 27 days (Nifty 500: −2.6%).
  • Q4 FY25: Revenue ₹677 cr (+9% year on year), EBITDA ₹93.0 cr (+8% year on year), PAT ₹63.0 cr (+34% year on year), EBITDA margin 13.7% (−13 bps). Score 82 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin fell 13 bps year on year. Tax rate 11%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +32.4% in 30 days (Nifty 500: +4.5%).
  • Q3 FY25: Revenue ₹557 cr (−8% year on year), EBITDA ₹62.0 cr (−13% year on year), PAT ₹37.0 cr (0% year on year), EBITDA margin 11.1% (−59 bps). Score 29 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was in line with it. EBITDA margin fell 59 bps year on year. Revenue fell 7% from last quarter.
  • Q2 FY25: Revenue ₹598 cr (−7% year on year), EBITDA ₹68.0 cr (−11% year on year), PAT ₹35.0 cr (−13% year on year), EBITDA margin 11.4% (−47 bps). Score 23 of 100, Below trend. EBITDA margin fell 47 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Aarti Drugs Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.